The influence of human platelet antigen match on the success of allogeneic peripheral blood progenitor cell transplantation following a reduced-intensity conditioning regimen

Transfusion

Volumn 45, Issue 2, 2005, Pages 195-201

  Leitner, Gerda C ^a   Stiegler, Gabriele ^a   Kalhs, Peter ^a   Greinix, Hildegard T ^a   Rabitsch, Werner ^a   Sillaber, Christian ^a   Hoecker, Paul ^a   Panzer, Simon ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOCYTE ANTIBODY; THROMBOCYTE ANTIGEN;

ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ALLOTYPE; ARTICLE; BLOOD DONOR; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MALE; MORTALITY; RECURRENT DISEASE; THROMBOCYTOPOIESIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIGENS, HUMAN PLATELET; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; RETROSPECTIVE STUDIES; THROMBOPOIESIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 13144297802     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2004.04115.x     Document Type: Article

References (36)

1. Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003;101:1620-9.
2. Maris B, Sandmaier BM, Maloney DG, et al. Non-myeloablative hematopoietic stem cell transplantation. Transfus Clin Biol 2001;8:231-4.
3. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with-graft-versus tumor effects. Blood 2001;97: 3390-400.
4. Feinstein L, Sandmaier BM, Hegenbart U, et al. Non-myeloablative allografting from human leukocyte antigenidentical sibling donors for treatment of acute myeloid leukaemia in first complete remission. Br J Haematol 2003;120:281-8.
5. Nademanee A, Schmidt GM, Parker P, et al. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using a molecular typing of donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood 1995;86:1228-34.
6. Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. N Engl J Med 1998;339:1177-85.
7. Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA Class I and II alleles in the donor and recipient. Blood 1998;92:3515-20.
8. Petersdorf EW, Hansen JA, Martin PJ, et al. Major-histocompatibility- complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med 2001;345: 1794-800.
9. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematological malignancies. Blood 2003;102: 2021-30.
10. Kernan NA. Minor histocompatibility antigens and marrow transplantation. N Engl J Med 1996;334:323-4.
11. Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev 1997;157:125-40.
12. Metcalfe P, Watkins NA, Ouwehand WH, et al. Nomenclature of human platelet antigens. Vox Sang 2003;85:240-5.
13. Minchinton RM, Waters AH, Kendra J, Barrett AJ. Autoimmune thrombocytopenia acquired from an allogeneic bone-marrow graft. Lancet 1982;2:627-9.
14. Minchinton RM, Waters AH, Malpas JS, et al. Platelet- and granulocyte-specific antibodies after allogeneic and autologous bone marrow grafts. Vox Sang 1984;46:125-35.
15. Taaning E, Jacobsen N, Morling N. Graft-derived anti HPA-2b production after allogeneic bone-marrow transplantation. Br J Hematol 1994;86:651-3.
16. Wernet D, Hinnak N, Schnaidt M. Reactivation of antibodies of donor and recipient origin to platelet antigens early after allogeneic bone marrow transplantation: a case report. Br J Haematol 1994;88:615-7.
17. Panzer S, Kiefel V, Bartram CR, et al. Immune thrombocytopenia more than a year after allogeneic marrow transplantation due to antibodies against donor platelets with anti-PlA1 specificity: evidence for a host-derived immune reaction. Br J Haematol 1989;71:259-64.
18. Bierling P, Pignon JM, Kuentz M, et al. Thrombocytopenia after bone marrow transplantation caused by a recipient origin Br(a) allo-antibody: presence of mixed chimerism 3 years after the graft without hematologic relapse. Blood 1994;83:274-9.
19. West KA, Anderson DR, McAuster VC, et al. Alloimmune thrombocytopenia after organ transplantation. N Engl J Med 1999;341:1504-7.
20. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89: 4531-6.
21. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematological diseases. Blood 1998;91:756-63.
22. Childs RW, Clave E, Tisdale J, et al. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. J Clin Oncol 1999;17:2044-9.
23. Worel N, Greinix HT, Schneider B, et al. Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems. Transfusion 2000;40: 543-50.
24. Pihusch R, Höhnberg B, Salat C, et al. Platelet flow cytometric findings in patients undergoing conditioning therapy for allogeneic hematopoietic stem cell transplantation. Ann Hematol 2002;81:454-61.
25. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981;57:267-76.
26. Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997;97:855-64.
27. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003;102: 756-62.
28. Klüter H, Fehlau K, Panzer S, et al. Rapid typing for human platelet antigen systems-1, -2, -3, and -5 by PCR amplification with sequence-specific primers. Vox Sang 1996;71:121-5.
29. Kiefel V, Santoso S, Weisheit M, Mueller-Eckhardt C. Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood 1987;7:1722-6.
30. Kurz M, Knöbl P, Kalhs P, et al. Platelet-reactive HLA antibodies associated with low posttransfusion platelet increments: a comparison between the monoclonal antibody-specific immobilization of platelet antigens assay and the lymphocytotoxicity test. Transfusion 2001;41:771-4.
31. Holensteiner A, Walchshofer S, Adler A, et al. Human platelet antigen gene frequencies in the Austrian population. Hemostasis 1995;25:133-6.
32. Bruno B, Gooley T, Sullivan KM, et al. Secondary failure of platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001;7:154-62.
33. A1 is expressed by cultured endothelial cells. Br J Haematol 1987;66:369-73.
34. Giltay JC, Brinkman HJ, Vlekke A, et al. The platelet glycoprotein Ia-IIa-associated Br-alloantigen system is expressed by cultured endothelial cells. Br J Haematol 1990;75:557-60.
35. Nash RA, Gooley T, Davis C, Appelbaum FR. The problem of thrombocytopenia after hematopoietic stem cell transplantation. Stem Cells 1996;14(Suppl 1):261-73.
36. Weissinger F, Sandmaier BM, Maloney DG, et al. Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood 2001;98:3584-8.